BACKGROUND: Limited data is available on comorbidity assessment in @entity1 with @entity2 . The present prospective study assessed the prevalence and association of the Charlson comorbidity index (CCI) and @entity8094 ( @entity8094 ) with clinical outcomes in @entity1 with newly diagnosed @entity2 undergoing chemotherapy. @entity1 AND METHODS: All @entity1 received histology-guided @entity902 doublets. The outcomes assessed were @entity1349 ( @entity1349 ), radiologic responses using Response Evaluation Criteria in @entity5 and @entity137 using the Common @entity137 Criteria, version 3.0. The groups analyzed were @entity8094   <= 9 (n  = 173) and > 9 (n  = 65) and CCI  = 0 (n  = 88), 1 (n  = 97), and  >=  2 (n  = 53). Correlations of the CCI and @entity8094 were assessed using Spearman's (rho) method. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for the factors affecting @entity1349 using Cox proportional hazard (CPH) modeling. RESULTS: Most @entity1 had @entity1442 (stage IIIB in 33.6%, stage IV in 42.4%). The median @entity8094 was 7 (interquartile range, 7-11), and the median CCI was 1 (interquartile range, 0-1). The correlation between the CCI and @entity8094 was moderate (rho  = 0.474; P  < .001). Age correlated weakly with both @entity8094 (rho  = 0.293; P  < .001) and CCI (rho  = 0.205; P  < .001). The @entity8094 > 9 group (vs. @entity8094   <= 9) had a significantly older mean age, @entity1 aged  >=  70 years, @entity1 , smokers, and squamous cell histologic type. The mean age in the CCI groups was 55.2 years for a CCI of 0, 59.6 years for a CCI of 1, and 60.3 years for a CCI of 2, with a statistically significant difference (P  = .002). The radiologic responses and @entity137 profiles were similar between the @entity8094 and CCI groups. The median @entity1349 was 287 days (95% CI, 232-342 days) and did not differ between the @entity8094 and CCI groups. On multivariate CPH analyses, worse @entity1349 was independently associated with stage IV disease (adjusted HR, 2.0; 95% CI, 1.4-2.7) and poor performance status (Eastern Cooperative Oncology Group score  >=  2; adjusted HR, 1.8; 95% CI, 1.1-2.8) but not with comorbidity, histologic type, or age. CONCLUSION: The @entity8094 and CCI scores correlated moderately with each other and weakly with age. The presence of comorbidities did not adversely influence clinical outcomes in this Indian cohort of @entity2 @entity1 undergoing first-line chemotherapy.

Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['men', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity8094 :: ('MESH:C566332', 'Disease') :: ['simplified comorbidity score', 'SCS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Solid Tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity2 :: (MESH:D008175,Disease) :: ['Lung Cancer']
